Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

Fred Hutchinson Cancer Center20 enrolled

Overview

This pilot clinical trial studies supportive care for patients with hematological malignancies undergoing hematopoietic cell transplant. Supportive care may improve quality of life in this patient population.

PRIMARY OBJECTIVES: I. Pilot a supportive care intervention that begins prior to transplantation and continues through the acute peritransplant period. II. Determine the proportion of patients who enroll and the level of comfort / distress of hematopoietic cell transplant (HCT) patients who meet with the supportive care team. III. Pilot data collection mechanisms and cost retrieval in preparation for a randomized clinical trial. OUTLINE: Patients undergo supportive care consultation before transplantation and at least once monthly while they remain at the transplant center.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Hematopoietic/Lymphoid Cancer

Interventions

palliative careOTHER

Undergo supportive care intervention

questionnaire administrationOTHER

Ancillary studies

quality-of-life assessmentPROCEDURE

Ancillary studies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * English as primary language * Planned autologous or allogeneic hematopoietic cell transplantation * Presence of co-morbidities (hematopoietic cell transplant co-morbidity index \[HCT-CI\] score 3 or greater), high risk disease (relapse risk \> 25%), or a planned type of transplant (human leukocyte antigen \[HLA\]-mismatched allogeneic or myeloablative) that places the patient at a higher than average risk of non-relapse mortality or relapse Exclusion Criteria: * Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach, as judged by the patient's medical team * First transplant of a planned tandem procedure (the second transplant is eligible)

Locations (1)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Seattle, Washington, United States

Outcomes

Primary Outcomes

Study participation rates defined as the proportion of patients who consent to enroll

Will mainly be descriptive.

Time frame: Up to 5 months

Completion time for the supportive care consultation

Will mainly be descriptive.

Time frame: Up to 90 days post-treatment

Level of comfort / distress attributed to individual parts of the consultation

Will mainly be descriptive. The post-consultation scores measuring level of comfort or distress per topic in the supportive care consultation will be summarized per item.

Time frame: Up to 90 days post-treatment

Completeness of follow-up data collection, where completeness is defined by the proportion of instrument scores that can be calculated per given time point

Will mainly be descriptive. The completeness of follow-up data collection will be calculated and reported as a proportion of successfully completed scales vs. scales attempted to be collected or completed by patients.

Time frame: Up to 90 days post-treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.